Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.1938
+0.0096 (5.21%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Company Description
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease.
The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025.
Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Ernexa Therapeutics Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Sanjeev Luther |
Contact Details
Address: 1035 Cambridge Street, Suite 18A Cambridge, Massachusetts 02141 United States | |
| Phone | 212 582 1199 |
| Website | ernexatx.com |
Stock Details
| Ticker Symbol | ERNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000748592 |
| CUSIP Number | 114082209 |
| ISIN Number | US1140822099 |
| Employer ID | 31-1103425 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanjeev Luther | Chief Executive Officer, President and Director |
| Sandra M. Gurrola | Principal Financial and Accounting Officer and Senior Vice President of Finance |
| Dorothy J. Clarke | General Counsel |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 14, 2025 | ARS | Filing |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | D | Notice of Exempt Offering of Securities |
| Apr 4, 2025 | SCHEDULE 13D/A | Filing |
| Apr 3, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 3, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 10-K | Annual Report |